Get in touch
555-555-5555
mymail@mailservice.com
Chem32 acquired by PQ Corporation: how business owners can capitalise on a post-COVID uptick
Glenn McGuire • Apr 19, 2021
CCD Partners Senior Advisor Glenn McGuire recently advised on the acquisition by PQ Corporation of Chem32, a founder-led supplier of catalyst pre-activation services in the US.
Reflecting on current market conditions and the outlook for the year ahead, Glenn shares his thoughts on how the Chem32 deal is representative of a broader trend as M&A activity picks back up after the initial slowdown caused by the coronavirus pandemic.
As we enter the second quarter of 2021, the impact of the pandemic continues to be widespread. Lockdowns persist to various degrees in the majority of countries around the world, and things are far from a return to anything resembling ‘normal’.
Despite this, however, the current outlook is considerably more positive for business owners considering their strategic options in the near future than it was this time last year, and the reason is relatively straightforward. When the pandemic first hit, a lot of M&A and strategic investment processes were delayed. COVID was an unknown, and reliable forecasting of revenue and business performance was challenging (if not altogether impossible) whilst nobody knew how governments and regulators would respond to the virus.
A year on from that point, while the market remains affected by COVID, buyers now have a much better understanding of the impact of the pandemic, and are consequently better positioned to take it into account in their reviews and valuations. From an opaque starting point in 2020, there is now a data point to reference and COVID is no longer the unknown that it was a year ago, a shift which has generated significantly more buyer confidence.
Strategics evaluating non-core assets in a post-COVID market
The pandemic was a disruptor to the status quo in M&A in many ways, and specifically in the speciality chemicals sector it had a clear impact. Over the past ten years, revenue growth has been strong in the market and it had been possible for companies to downplay the prominence of non-core businesses on the balance sheet.
The pandemic has allowed the sector to take a breather, and many companies have taken the opportunity to re-evaluate their portfolios. This re-evaluation has, for many, included exploration of how best to realize the value of their non-core assets.
The strategics are already reviewing their portfolios and divesting non-core businesses, but they are also simultaneously acquiring to broaden and strengthen their product offerings to customers. We have already seen many examples of this in Q1 2021. I have always been a firm believer in the ‘best owner’ philosophy, and as a result I expect to see a lot of transfer of assets in 2021 as this re-alignment and carve-out of non-core businesses continues.
Opportunities for Owners and Founders
Niche owner-managed in the Specialty Chemicals sector have thus far enjoyed strong growth in a niche markets on the back of significant industry growth in specialty Chemicals. Based on recent consulting engagements and ongoing market data, the case can be made that it is also an optimal time for small business owners to roll up into larger organizations.
Strategic are looking for quality bolt-on opportunities to broaden their core services offering to customers. A challenge for many smaller chemical companies is that they may have many potential growth opportunities, but with the current market outlook realizing those growth opportunities in partnership or as part of a larger organization.
For owner-managed companies interested in monetizing their business, presenting a clear picture of the core business, and scoping out key growth opportunities is the key to maximizing value for both buyer and seller. Consider a few important questions:
- Q1 “What do I have today” - what, realistically, is my current core business offering?
- Q2 “What is my businesses’ potential” – what are the 1-2 growth opportunities where my company has a competitive advantage?
- Q3 “Who is the best owner to realize my growth opportunities” – a buyer's valuation will be based on their ability to realize the growth opportunities.
A year on from the beginning of global lockdowns, recent market dynamics have meant that it is once again it is viable for sellers to engage with prospective buyers without the “question mark” of the pandemic clouding discussions as it once did. Buyers are better prepared and informed to factor in the impact of COVID, and the eagerness for larger firms to capitalize on the disruption to global commerce has created an exciting time to explore potential deals.
CCD Partners is a consultancy specialised in corporate transformations in small and mid-market chemicals and life sciences businesses.
To organise a call with one of our partners please email contact@ccdpartners.com
Receive M&A news relevant to your business
At critical moments our clients engage us to provide pre-publicity "off-market" intelligence to give them the edge over the competition - we also provide up-to-the-minute public or "on-market" intelligence for free
Contact Us
RECENT POSTS
Market leading provider of formulated chemical process aids and foam control, PennWhite has been acquired by Manali Petrochemicals, part of the AM International Holdings group.
Global source of industrial gas news, views, and debate, gas world has been sold by John and Karen Raquet to the senior management team in an MBO, backed by Mobeus Equity Partners.
Polyblend UK Ltd is one of the market leaders in PVC based polymers. We are experts in manufacturing a comprehensive range of liquid plastisol and dispersion systems, complemented by our Speciality Distribution business supplying plasticisers, resins and PVC additives.
GFBiochemicals is a sustainable chemicals company that produces levulinic acid derivatives at commercial scale directly from biomass. Having perfected its technology, product, and certification, the company is entering a new phase of commercialization.
In the latest episode of the Chemical Transformations podcast , CCD Partners' Managing Partner Matt Dixon speaks with Ted Clark, former President and CEO of Royal Adhesives & Sealants, discussing his new book "Shipping Clerk to CEO: The Power of Curiosity, Will, and Self Directed Learning”. The book tells the story of Clark’s remarkable career journey from entry-level worker to CEO of a $240m chemical company by the age of 42.
Esteve Química purchases one of the UQUIFA Group's two pharmaceutical fine chemicals plants in Barcelona.
Specialty materials manufacturer Vertellus has acquired Polyscope Polymers B.V., a global leader in specialty additives for coatings, electronics applications, and engineering polymers.
Biosynth Carbosynth is a fully hybrid Research Products, Life Sciences Reagents and Custom Synthesis and Manufacturing Services Company with global research, manufacturing and distribution facilities. They are the supplier of choice for many in the pharmaceutical, life science, food, agrochemical, cosmetic and diagnostic sectors and manufacture and source a vast range of chemical and biochemical products.
Steve Allin co-founded Charnwood Molecular with Phil Page in 1998. 22 years later, the business has evolved dramatically from its origins as a spinout of Loughborough University. Backed by a partnership with Synova Capital, the company is now preparing to move into a former AstraZeneca research facility and has already completed its first M&A deal, acquiring Aurelia Bioscience in summer 2021. CCD Partners’ Matt Dixon spoke with Steve about the journey from full-time academia to running a high-growth market leader.
Aspire was founded in 2009. Aspire has an asset-light business model that focuses on R&D, business development and sales and marketing, while outsourcing manufacturing and distribution to specialist third parties. For more details see www.aspirepharma.co.uk.
CCD Partners
Insight | Network | Execution
We are a network of multi-disciplinary specialists united in the common purpose of identifying and delivering the full potential of innovative and impactful chemicals and life sciences businesses.
Get In Touch
